Does TUDCA actually protect the liver during an oral steroid cycle?

Clinical and pre-clinical evidence shows TUDCA shifts the bile-acid pool toward less-cytotoxic species, reduces ALT/AST elevation in cholestatic liver injury models, and improves hepatocyte mitochondrial function. It is not a license to extend cycles indefinitely — it lowers the magnitude of injury, it does not eliminate it.

When do I start TUDCA — before, during or after the cycle?

Standard practice is to start TUDCA on day 1 of any 17α-alkylated oral and continue for two to four weeks past the last dose, as ALT and AST typically peak after the cycle ends rather than during it.

Can I take TUDCA together with NAC and milk thistle?

Yes. The three act on different pathways — TUDCA on bile-acid composition, NAC on glutathione synthesis, milk thistle (silymarin) on antioxidant signalling. The combination is additive, not redundant, and is well-tolerated.

TUDCA and on-cycle liver support, explained

Updated 2026-04-30 · Reviewed by the DeusPowershop editorial team

Tauroursodeoxycholic acid — TUDCA — is the taurine-conjugated form of ursodeoxycholic acid, a bile acid that has been used clinically for decades to treat cholestatic liver disease. In the past ten years it has become the default on-cycle hepatoprotectant in the strength community because the mechanism of action overlaps closely with the kind of injury 17α-alkylated oral steroids cause: intrahepatic cholestasis. For background see TUDCA on Wikipedia and the 2014 review of TUDCA in liver disease (PMC4214858).

Why oral steroids damage the liver

Compounds in the oral-steroid category — Anavar (oxandrolone), Winstrol (stanozolol), Dianabol (methandrostenolone), Anadrol (oxymetholone), Superdrol — share a 17α-alkyl modification that lets them survive first-pass hepatic metabolism. The same modification interferes with bile-acid export. The result is intrahepatic cholestasis: bile builds up inside the hepatocyte and triggers oxidative stress, mitochondrial dysfunction and the ALT/AST elevation visible on bloodwork.

How TUDCA helps

Bile-acid pool replacement: TUDCA dilutes the more cytotoxic endogenous bile acids (chenodeoxycholic, deoxycholic) with a hydrophilic, less-toxic species.
Mitochondrial stabilisation: animal models show TUDCA preserves the mitochondrial membrane potential under cholestatic stress.
Endoplasmic-reticulum stress: TUDCA acts as a chemical chaperone, reducing ER-stress signalling that drives hepatocyte apoptosis.

Practical dosing on a 6-week oral cycle

Phase	TUDCA dose	Notes
Cycle weeks 1–6	500 mg/day	Split AM/PM with meals
Wash-out weeks 7–10	250–500 mg/day	Continue until repeat ALT/AST is at baseline

Stacking with NAC and milk thistle

N-acetyl cysteine restores hepatic glutathione, the cell's primary antioxidant. Silymarin (the active extract of milk thistle) modulates inflammatory signalling and stabilises the hepatocyte membrane. Each targets a different limb of the same problem, so stacking TUDCA + NAC + silymarin during oral cycles is additive rather than redundant. A common daily structure is 500 mg TUDCA, 600–1200 mg NAC and 150–300 mg standardised silymarin, all with food.

Bloodwork that matters

Take a baseline panel before the cycle: ALT, AST, ALP, total and direct bilirubin, GGT, full lipids. Repeat at the end of the cycle and again four weeks after the last oral dose. ALT/AST commonly peak in that post-cycle window — TUDCA is therefore continued until the repeat panel is clean.

Where to go next

Browse the health-products category for TUDCA and ancillary support.
Read Post-cycle therapy explained for the SERM/AI side of recovery.
Compare oral compound profiles in the oral steroids catalog.